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Ensuring Access to Medications in the US
During the COVID-19 Pandemic
The coronavirus disease 2019 (COVID-19) pandemic
continues to rapidly evolve. Given the origins of
COVID-19 in China, there were initial concerns regard-
ing medication shortages due to the reliance of the US
on overseas manufacturing of active pharmaceutical
ingredients.1,2 Although no major disruptions in phar-
maceutical access have occurred thus far, the future of
the pandemic and its effect on the US drug supply re-
mains far from certain.
The pharmaceutical supply chain represents a series
of interdependent steps that ultimately produce the prod-
ucts that are used by consumers in the US. From manufac-
turers, pharmaceuticals are shipped through wholesalers
or distributors and on to retail, specialty, and mail-order
pharmacies as well as to hospitals, nursing homes, prisons,
clinics, and other sites of care. Retail pharmacies have an
especially important role in this process, dispensing more
than 85% of all prescription medications in the US.3 From
manufacturers to end users, the pharmaceutical supply
chain is vast, employing tens of thousands of workers who
manage the annual distribution of an estimated nearly
6 billion prescriptions in the US.3
Although early reports regarding drug shortages
have focused on overseas manufacturing, the effect
of the COVID pandemic on the distribution of medi-
cines within the US is also a concern. There have been
reports that some pharmacies have closed due to the
pandemic, and widespread illness, quarantines, and
social distancing measures may increasingly disrupt
pharmacy access. In addition, given a surge in demand
for certain types of health care, there will be height-
ened need for many medicines such as those used to
treat respiratory disease and critical illness.4 There may
also be demand surges for specific medicines based on
media coverage, emerging evidence of benefit, or
other factors. These events, such as those that have
already occurred for acetaminophen and hydroxychlo-
roquine, may contribute to “stock outs” at distributors
and pharmacies and, if left unregulated, worsened
access for many in need.5,6 Federal and state regula-
tors, as well as distributors and pharmacies, should take
several emergency response and preparedness mea-
sures to address these possibilities.
Develop an Essential Medicines Strategy
Federal and state preparedness efforts should focus on
what the World Health Organization (WHO) considers
“essential medicines,” which are medicines that satisfy
the priority health needs of the population and should
be available in the health system at all times, in
adequate amounts, with quality ensured, and at a price
the individual and community can afford.7 Such treat-
ments include antibiotics, antivirals, antidiabetic
agents, cardiovascular drugs, respiratory agents,
contraceptives, mental health products, and analge-
sics. To implement an essential medicines strategy,
the US Food and Drug Administration (FDA) should
first develop a list of essential medicines. Such a list is
critical in shaping regulations that ensure access to
essential medicines is not interrupted during this and
future crises.
Prevent Stockpiling and Drug Shortages
Efforts are needed to guard against surges in medication
use as well as stockpiling that may cause shortages and
inequitable access. One major wholesaler recently an-
nounced steps to protect its inventory, in-
cluding to identify and mitigate the risk of
drug shortages by allocating specific prod-
ucts, includingantibiotics,antiviralagents,
and respiratory medicines.8 This alloca-
tion strategy should include other essen-
tial medicines and be required for all
wholesalers. Restricting the retail dispens-
ing of essential medicines to a 30-day
emergency supply, including for cash-
paying customers, would also reduce the likelihood of
demand surges and drug shortages.
Expand Capacity for Mail-order
and Home Delivery
Rapid increases in the capacity for mail-order and home
delivery are vital. Many retail pharmacies do not offer
home-delivery services, and mail-order pharmacies ac-
count for less than 10% of all retail prescriptions dis-
pensed in the US.3 The scope of these delivery systems
should be increased given potential for quarantines or
widespread pharmacy closures. Following the lead of
several large pharmacy chains,9 public and private pay-
ers should also provide incentives for pharmacies, par-
ticularly independent stores located in underserved
areas, to offer home delivery services at no cost.
Finance an Emergency Supply of Essential
Medicines
Given the uncertainty around where and when disrup-
tions to the supply chain may take place, health care
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insurers are also relaxing refill criteria, so as to allow for individu-
als to stockpile additional medicines. For example, some insurers
have announced policies that waive typical refill “windows,”
thereby allowing for early refills for individuals to ensure a suffi-
cient stockpile at home in the event of abrupt disruptions in
medication access.9 These measures are necessary but may not
be sufficient for the millions of US residents already burdened by
their out-of-pocket prescription costs; payors should also con-
sider waiving co-payments, particularly for low-income individu-
als, so as to allow them to stockpile emergency supplies of essen-
tial medicines.
Implement a Long-term Strategy to Safeguard Access
While the nation and world are rightly focused on the COVID-19 pan-
demic, this is not the first time that national emergencies have threat-
ened medication access in the US, nor will it be the last. To foster
emergency preparedness, federal and state public health agencies
should establish and maintain central inventories of essential medi-
cines that can be distributed at state or local levels based on need.
The security of such national stockpiles would be further enhanced
by increasing domestic production of these medicines so as to pro-
tect the supply chain and product availability from unpredictable
global events, such as other countries’ decisions to cease import-
ing specific products into the US.4
Even if these steps were undertaken, there is no guarantee that
new challenges would not arise. For example, what if a product such
as tocilizumab, which is in clinical trials as a treatment to manage the
cytokine storm associated with fulminant viral pneumonia, proves
efficacious as a treatment for patients with COVID-19 and severe re-
spiratory compromise? Is the supply chain prepared for this? Are price
controls in place to protect the public and ensure that patients have
access to this “essential medicine”? Who will pay for the soaring
demand for such a treatment?
For many individuals in the US, barriers to accessing medicines
are nothing new. Economic, clinical, social, and structural factors
cause many individuals to go without essential medicines every day.
However, the COVID-19 pandemic poses urgent and in some cases,
novel challenges, and does so on an order of magnitude greater than
ever before. Fortunately, rapid mobilization and transformation of
the pharmaceutical manufacturing and distribution system is pos-
sible, and many who are involved with and affect the supply chain,
ranging from regulators to distributors to pharmacies, have al-
ready demonstrated a commitment to meet challenges that arise.
Despite this, there is more work to do, and not a moment to lose.
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